Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (371-380 of 385) with videos related to

Pageof 39
Sort By:
European Heart Journal|August 30, 2025
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial)Markus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Blood|July 12, 2015
Disease evolution and outcomes in familial AML with germline CEBPA mutationsKiran Tawana, Jun Wang, Aline Renneville, et al.
Haematologica|November 7, 2024
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY AllianceMarta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, et al.
Blood|October 25, 2021
PLCG1 is required for AML1-ETO leukemia stem cell self-renewalTina M Schnoeder, Adrian Schwarzer, Ashok Kumar Jayavelu, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Cell Stem Cell|May 6, 2022
Antigen presentation safeguards the integrity of the hematopoietic stem cell poolPablo Hernández-Malmierca, Dominik Vonficht, Alexandra Schnell, et al.
Nature Genetics|November 8, 2016
The genomic landscape of core-binding factor acute myeloid leukemiasZachary J Faber, Xiang Chen, Amanda Larson Gedman, et al.
Cell|January 24, 2012
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutationsTobias Rausch, David T W Jones, Marc Zapatka, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Pageof 39

Showing results (371-380 of 385) with videos related to

Sort By:
Pageof 39
European Heart Journal|August 30, 2025
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial)Markus S Anker, Amir A Mahabadi, Matthias Totzeck, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Blood|July 12, 2015
Disease evolution and outcomes in familial AML with germline CEBPA mutationsKiran Tawana, Jun Wang, Aline Renneville, et al.
Haematologica|November 7, 2024
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY AllianceMarta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, et al.
Blood|October 25, 2021
PLCG1 is required for AML1-ETO leukemia stem cell self-renewalTina M Schnoeder, Adrian Schwarzer, Ashok Kumar Jayavelu, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Cell Stem Cell|May 6, 2022
Antigen presentation safeguards the integrity of the hematopoietic stem cell poolPablo Hernández-Malmierca, Dominik Vonficht, Alexandra Schnell, et al.
Nature Genetics|November 8, 2016
The genomic landscape of core-binding factor acute myeloid leukemiasZachary J Faber, Xiang Chen, Amanda Larson Gedman, et al.
Cell|January 24, 2012
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutationsTobias Rausch, David T W Jones, Marc Zapatka, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Pageof 39